Pharmacokinetic Study of Linezolid for TB Meningitis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

July 20, 2023

Conditions
Tuberculosis, MeningealLinezolid
Interventions
DRUG

Linezolid

"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."

Trial Locations (1)

40161

Hasan Sadikin General Hospital, Bandung

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

collaborator

Global Alliance for TB Drug Development

OTHER

lead

Universitas Padjadjaran

OTHER